DCTH:NASDAQ
Delcath Systems Inc
$14.32
arrow_upward
+1.70%(+0.24) 1D
Oct 19, 12:09:35 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DCTH...
Open
$14.16
High
$14.33
Low
$14.08
Mkt. cap
496.89M
Avg. vol.
335.45K
Volume
45.63K
P/E ratio
2,343.70
52-wk high
$17.42
52-wk low
$8.12
EPS
$0.01
Beta
0.60
Shares outstanding
34.70M
No. of employees
156
Open
$14.16
High
$14.33
Low
$14.08
Mkt. cap
496.89M
Avg. vol.
335.45K
Volume
45.63K
P/E ratio
2,343.70
52-wk high
$17.42
52-wk low
$8.12
EPS
$0.01
Beta
0.60
Shares outstanding
34.70M
No. of employees
156
News stories
From web sources and news partners
https://www.dars.gov.et/
·
2 weeks ago
DCTH Q2 2026 Earnings: Positive EPS Surprise Meets a Muted Share Reaction - Post-Earnings Reaction
https://www.dars.gov.et/
·
1 month ago
DCTH Q2 2026 Earnings: EPS of $0.07 vs. -$0.0918 Estimate Delivers a 176.25% Upside Surprise - Pre-Earnings Drift
Profile
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally. Wikipedia
About Delcath Systems Inc
CEOGerard Michel
Employees156
Founded1988
HeadquartersQueensbury, New York, United States
SectorMedical device
Websitedelcath.com